Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Galantamine Hydrobromide

FDA-approved product (tablet, oral), marketed as Galantamine Hydrobromide, Razadyne, Razadyne Er.

Registered studies
50+
Lab records
1
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Galantamine Hydrobromide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Alzheimer disease
  • Dementia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Anticholinesterases
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA35.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli33.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae89.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis57.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • K. pneumoniae: measured active in 1 of 1 lab record
Open Galantamine Hydrobromide in ChEMBL Registered studies below
Show the 1 laboratory record, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-5.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-5.4 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-5.9 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Galantamine Hydrobromide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Safety and Tolerability Study of Extended Release (ER) Galantamine in Alzheimer's Disease

    NCT00082602 · start 2004-05

    Registered record
    Registry ID
    NCT00082602
    Conditions
    Alzheimer's Disease
    Interventions
    galantamine ER
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2004-05
    Completion
    2005-04
    Enrolment
    83

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer's Disease
    Interventiongalantamine ER
    PhasePhase 3
    Registry statusCompleted

  • Galantamine for Cognition in People With Schizophrenia

    NCT00320736 · start 2004-01

    Registered record
    Registry ID
    NCT00320736
    Conditions
    Schizophrenia; Schizoaffective Disorder
    Interventions
    galantamine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2004-01
    Completion
    2006-05
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Schizoaffective Disorder
    Interventiongalantamine
    PhasePhase 4
    Registry statusCompleted

  • Treatment of Severe Alzheimer's Disease: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Controlled Study

    NCT00216593 · start 2003-12

    Registered record
    Registry ID
    NCT00216593
    Conditions
    Dementia; Alzheimer Disease
    Interventions
    galantamine hydrobromide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2003-12
    Completion
    2008-03
    Enrolment
    415

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDementia; Alzheimer Disease
    Interventiongalantamine hydrobromide
    PhasePhase 3
    Registry statusCompleted

  • Rivastigmine Monotherapy and Combination Therapy With Memantine in Patients With Moderately Severe Alzheimer's Disease Who Failed to Benefit From Previous Cholinesterase Inhibitor Treatment

    NCT00234637 · start 2003-11

    Registered record
    Registry ID
    NCT00234637
    Conditions
    Alzheimer's Disease
    Interventions
    Rivastigmine, memantine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2003-11
    Completion
    2005-06
    Enrolment
    204

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer's Disease
    InterventionRivastigmine, memantine
    PhasePhase 4
    Registry statusCompleted

  • Galantamine Augmentation of Escitalopram for Treatment of Depression

    NCT00423969 · start 2003-11

    Registered record
    Registry ID
    NCT00423969
    Conditions
    Depression
    Interventions
    Galantamine; Escitalopram
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2003-11
    Completion
    2005-09
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepression
    InterventionGalantamine; Escitalopram
    PhasePhase 4
    Registry statusTerminated

  • A Double-Blind, Placebo-Controlled Study of Galantamine to Improve Cognitive Dysfunction in Bipolar Disorder

    NCT00195845 · start 2003-04

    Registered record
    Registry ID
    NCT00195845
    Conditions
    Bipolar Disorder
    Interventions
    Galantamine; Placebos
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2003-04
    Completion
    2007-02
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar Disorder
    InterventionGalantamine; Placebos
    PhasePhase 4
    Registry statusCompleted

  • Acetylcholinesterase Inhibitors to Improve Cognitive Function and Overall Rehabilitation After a Stroke

    NCT00227994 · start 2003-04

    Registered record
    Registry ID
    NCT00227994
    Conditions
    Cerebrovascular Accident
    Interventions
    Galantamine; Donepezil
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2003-04
    Completion
    2005-03
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCerebrovascular Accident
    InterventionGalantamine; Donepezil
    PhasePhase 4
    Registry statusCompleted

  • A Survey Study of the Treatment and Outcome Management in Patients Diagnosed With Alzheimer's Disease

    NCT00291421 · start 2002-07

    Registered record
    Registry ID
    NCT00291421
    Conditions
    Alzheimer Disease; Dementia; Nervous System Diseases; Mental Disorders; Brain Diseases
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2002-07
    Completion
    2006-05
    Enrolment
    2,360

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer Disease; Dementia; Nervous System Diseases; Mental Disorders +1 more
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia

    NCT00176423 · start 2002-05

    Registered record
    Registry ID
    NCT00176423
    Conditions
    Schizophrenia; Schizoaffective Disorder
    Interventions
    galantamine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2002-05
    Completion
    2006-12
    Enrolment
    117

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Schizoaffective Disorder
    Interventiongalantamine
    PhasePhase 4
    Registry statusCompleted

  • A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment

    NCT00236431 · start 2001-05

    Registered record
    Registry ID
    NCT00236431
    Conditions
    Dementia; Alzheimer Disease
    Interventions
    Galantamine hydrobromide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2001-05
    Completion
    2003-12
    Enrolment
    1,063

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDementia; Alzheimer Disease
    InterventionGalantamine hydrobromide
    PhasePhase 3
    Registry statusCompleted

  • An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease.

    NCT00301574 · start 2001-04

    Registered record
    Registry ID
    NCT00301574
    Conditions
    Alzheimer Disease
    Interventions
    galantamine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2001-04
    Completion
    2004-02
    Enrolment
    398

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer Disease
    Interventiongalantamine
    PhasePhase 3
    Registry statusCompleted

  • Placebo-Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: Safety and Efficacy of a Controlled-Release Formulation

    NCT00253214 · start 2001-03

    Registered record
    Registry ID
    NCT00253214
    Conditions
    Alzheimer Disease; Dementia
    Interventions
    galantamine hydrobromide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2001-03
    Completion
    2002-07
    Enrolment
    973

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer Disease; Dementia
    Interventiongalantamine hydrobromide
    PhasePhase 3
    Registry statusCompleted

  • Long-term Safety and Efficacy of Galantamine in Alzheimer's Disease

    NCT00304629 · start 2000-03

    Registered record
    Registry ID
    NCT00304629
    Conditions
    Alzheimer Disease
    Interventions
    galantamine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2000-03
    Completion
    2002-03
    Enrolment
    241

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer Disease
    Interventiongalantamine
    PhasePhase 3
    Registry statusCompleted

  • A Study of the Safety and Effectiveness of Galantamine Versus Placebo in the Treatment of Patients With Vascular Dementia or Mixed Dementia

    NCT00261573 · start 1998-12

    Registered record
    Registry ID
    NCT00261573
    Conditions
    Alzheimer Disease; Vascular Dementia
    Interventions
    galantamine hydrobromide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1998-12
    Completion
    2000-12
    Enrolment
    593

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer Disease; Vascular Dementia
    Interventiongalantamine hydrobromide
    PhasePhase 3
    Registry statusCompleted

  • A Study of the Safety and Effectiveness of a Flexible Dose of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease

    NCT00253227 · start 1997-07

    Registered record
    Registry ID
    NCT00253227
    Conditions
    Alzheimer Disease; Dementia
    Interventions
    galantamine hydrobromide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1997-07
    Completion
    1998-12
    Enrolment
    387

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer Disease; Dementia
    Interventiongalantamine hydrobromide
    PhasePhase 3
    Registry statusCompleted